Tobias Gedde-Dahl

• Montoro, Juan; Eikema, Dirk-Jan; Tuffnell, Joe; Potter, Victoria; Kalwak, Krzysztof & Halkes, Constantijn J. M. [Show all 27 contributors for this article] (2024). Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT. Blood. ISSN 0006-4971. doi: 10.1182/blood.2024024173.
• Nagler, Arnon; Labopin, Myriam; Swoboda, Ryszard; Schroeder, Thomas; Hamladji, Rose-Marie & Griskevicius, Laimonas [Show all 21 contributors for this article] (2024). Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-024-02284-5.
• Ye, Yishan; Labopin, Myriam; Gérard, Socié; Yakoub-Agha, Ibrahim; Blau, Igor Wolfgang & Aljurf, Mahmoud [Show all 22 contributors for this article] (2024). Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. ISSN 0361-8609. doi: 10.1002/ajh.27342.
• Loke, Justin; Labopin, Myriam; Craddock, Charles; Socié, Gérard; Gedde-Dahl, Tobias & Blaise, Didier [Show all 23 contributors for this article] (2024). Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study. Cancer. ISSN 0008-543X. doi: 10.1002/cncr.35308.
• Penack, Olaf; Abouqateb, Mouad; Peczynski, Christophe; Boreland, William; Kröger, Nicolaus & Stelljes, Matthias [Show all 18 contributors for this article] (2024). ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. ISSN 0887-6924. doi: 10.1038/s41375-024-02225-7.
• Guièze, Romain; Eikema, Diderik-Jan; Koster, Linda; Schetelig, Johannes; Sengeloev, Henrik & Passweg, Jakob [Show all 26 contributors for this article] (2024). Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-024-02256-9.
• Penack, Olaf; Abouqateb, Mouad; Peczynski, Christophe; Boreland, William; Gülbas, Zafer & Gedde-Dahl, Tobias [Show all 18 contributors for this article] (2024). PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer Journal. ISSN 2044-5385. 14(1). doi: 10.1038/s41408-024-01032-8.
• Holland, Petter; Istre, Mette Stausland; Ali, Maryan Mohamed; Gedde-Dahl, Tobias; Buechner, Jochen & Wildhagen, Mari [Show all 12 contributors for this article] (2024). Epigenetic aging of human blood cells is influenced by the age of the host body. Aging Cell. ISSN 1474-9718. doi: 10.1111/acel.14112.
• Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne; Koskenvesa, Perttu & Stenke, Leif [Show all 20 contributors for this article] (2024). Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial. Leukemia. ISSN 0887-6924. doi: 10.1038/s41375-024-02145-6.
• McDonald, George B.; Landsverk, Ole J. B.; McGovern, Dermot P.B.; Aasebø, Anders Theodor Michaelsen; Paulsen, Vemund & Haritunians, Talin [Show all 14 contributors for this article] (2024). Allogeneic bone marrow transplantation for patients with treatment-refractory Crohn's Disease. Heliyon. ISSN 2405-8440. 10(1). doi: 10.1016/j.heliyon.2024.e24026.
• Moukalled, Nour; Labopin, Myriam; Versluis, Jurjen; Socié, Gérard; Blaise, Didier & Salmenniemi, Urpu [Show all 19 contributors for this article] (2024). Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. American Journal of Hematology. ISSN 0361-8609. doi: 10.1002/ajh.27187.
• Poiré, Xavier; Labopin, Myriam; Polge, Emmanuelle; Ganser, Arnold; Socié, Gérard & Gedde-Dahl, Tobias [Show all 17 contributors for this article] (2023). Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-023-02167-1.
• Gjærde, Lars Klingen; Ruutu, Tapani; Peczynski, Christophe; Boreland, William; Kröger, Nicolaus & Blaise, Didier [Show all 20 contributors for this article] (2023). The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-023-02154-6. Full text in Research Archive
• Spyridonidis, Alexandros; Labopin, Myriam; Gedde-Dahl, Tobias; Ganser, Arnold; Stelljes, Matthias & Craddock, Charles [Show all 30 contributors for this article] (2023). Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-023-02139-5. Full text in Research Archive
• Bazarbachi, Ali; Labopin, Myriam; Gedde-Dahl, Tobias; Remenyi, Peter; Forcade, Edouard & Kröger, Nicolaus [Show all 18 contributors for this article] (2023). Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party. Clinical Cancer Research. ISSN 1078-0432. 29(21), p. 4441–4448. doi: 10.1158/1078-0432.CCR-23-0954.
• Giannakopoulou, Eirini Chrysovalantou; Lehander, Madeleine; Virding Culleton, Stina; Yang, Weiwen; Li, Yingqian & Kärpänen, Terhi Hannele [Show all 29 contributors for this article] (2023). A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nature Cancer. 4(10). doi: 10.1038/s43018-023-00642-8. Full text in Research Archive
• Nagler, Arnon; Labopin, Myriam; Kröger, Nicolaus; Schroeder, Thomas; Gedde-Dahl, Tobias & Eder, Matthias [Show all 14 contributors for this article] (2023). The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-023-02095-0.
• Hernández-Boluda, Juan Carlos; Eikema, Diderik-Jan; Koster, Linda; Kröger, Nicolaus; Robin, Marie & de Witte, Moniek [Show all 26 contributors for this article] (2023). Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-023-02094-1.
• Sanz, Jaime; Labopin, Myriam; Pabst, Thomas; Versluis, Jurjen; Van Gorkom, Gwendolyn & Meijer, Ellen [Show all 17 contributors for this article] (2023). Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-023-02075-4.
• Federico, Lorenzo; Tvedt, Tor Henrik Anderson; Gainullin, Murat; Osen, Julie Røkke; Chaban, Viktoriia & Lund, Kathrine Persgård [Show all 19 contributors for this article] (2023). Robust spike-specific CD4⁺ and CD8⁺ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study. Frontiers in Immunology. ISSN 1664-3224. 14. doi: 10.3389/fimmu.2023.1210899. Full text in Research Archive
• Al Hamed, Rama; Ngoya, Maud; Galimard, Jacques-Emmanuel; Sengeloev, Henrik; Gedde-Dahl, Tobias & Kulagin, Aleksandr [Show all 18 contributors for this article] (2023). Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia—Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study. Cancer. ISSN 0008-543X. doi: 10.1002/cncr.34843.
• Nagler, Arnon; Labopin, Myriam; Mielke, Stephan; Passweg, Jakob; Blaise, Didier & Gedde-Dahl, Tobias [Show all 20 contributors for this article] (2023). Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-023-01980-y.
• Ali, Maryan Mohamed; Gedde-Dahl, Tobias; Osnes, Liv T. N.; Perrier, Flavie; Veierød, Marit Bragelien & Tjønnfjord, Geir Erland [Show all 7 contributors for this article] (2023). Extracorporeal Photopheresis as Graft-versus-Host Disease Prophylaxis: A Randomized Controlled Trial. Transplantation and Cellular Therapy (TCT). ISSN 2666-6375. 29(6), p. 364.e1–364.e11. doi: 10.1016/j.jtct.2023.02.023. Full text in Research Archive
• Vo, Camilla Dao; Myhre, Anders Eivind; Abrahamsen, Ingerid Weum; Remberger, Mats; Mattsson, Jonas & Fløisand, Yngvar [Show all 10 contributors for this article] (2023). Allogen stamcelletransplantasjon hos voksne 2015–21. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(4). doi: 10.4045/tidsskr.22.0521. Full text in Research Archive
• Geelen, Inge G.P.; Gullaksen, Stein-Erik; Ilander, Mette M.; Olssen-Strömberg, Ulla; Mustjoki, Satu & Richter, Johan [Show all 15 contributors for this article] (2023). Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Annals of Hematology. ISSN 0939-5555. doi: 10.1007/s00277-023-05199-1.
• Albert, Michael H.; Sirlait, Tiarlan; Eikema, Dirk-Jan; Bakunina, Katerina; Wehr, Claudia & Suarez, Felipe [Show all 51 contributors for this article] (2022). Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood. ISSN 0006-4971. 140. doi: 10.1182/blood.2022015506.
• Nagler, Arnon; Ngoya, Maud; Jacques-Emmanuel, Galimard; Labopin, Myriam; Kröger, Nicolaus & Socié, Gerard [Show all 19 contributors for this article] (2022). Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-022-01825-0.
• Garcia-Horton, Alejandro; Cyriac, Sunu L.; Gedde-Dahl, Tobias; Fløisand, Yngvar; Remberger, Mats & Mattsson, Jonas [Show all 7 contributors for this article] (2022). Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups. European Journal of Haematology. ISSN 0902-4441. 109(6), p. 672–679. doi: 10.1111/ejh.13850.
• Huuhtanen, Jani; Ilander, Mette; Yadav, Bhagwan; Dufva, Olli M.J.; Lähteenmäki, Hanna & Kasanen, Tiina [Show all 26 contributors for this article] (2022). IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. Journal of Clinical Investigation. ISSN 0021-9738. 132(17). doi: 10.1172/JCI152585. Full text in Research Archive
• Tvedt, Tor Henrik Anderson; Rose-John, Stefan; Tsykunova, Galina; Ahmed, Aymen B; Gedde-Dahl, Tobias & Ersvær, Elisabeth [Show all 7 contributors for this article] (2022). IL-6 Responsiveness of CD4⁺ and CD8⁺ T Cells after Allogeneic Stem Cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin Therapy. Journal of Clinical Medicine. ISSN 2077-0383. 11(9). doi: 10.3390/jcm11092530. Full text in Research Archive
• Nagler, Arnon; Galimard, Jacques-Emmanuel; Labopin, Myriam; Blaise, Didier; Arcese, William & Trisolini, Silvia Maria [Show all 15 contributors for this article] (2022). Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT. Cancer Medicine. ISSN 2045-7634. doi: 10.1002/cam4.5039. Full text in Research Archive
• Swan, Dawn; Hayden, Patrick J.; Eikema, Dirk-Jan; Koster, Linda; Sauer, Sandra & Blaise, Didier [Show all 25 contributors for this article] (2022). Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. British Journal of Haematology. ISSN 0007-1048. 197(1), p. 82–96. doi: 10.1111/bjh.18025.
• Nagler, Arnon; Labopin, Myriam; Craddock, Charles; Socié, Gerard; Yakoub-Agha, Ibrahim & Gedde-Dahl, Tobias [Show all 15 contributors for this article] (2022). Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated acute myeloid leukemia patients: On behalf of the acute leukemia working party/European society of blood and marrow transplantation. American Journal of Hematology. ISSN 0361-8609. 97(3), p. 274–282. doi: 10.1002/ajh.26442.
• Aasebø, Anders Theodor Michaelsen; Gedde-Dahl, Tobias; Reims, Henrik Mikael; Bækkevold, Espen Sønderaal & Jahnsen, Frode Lars (2022). Calprotectin Expressing Donor-Derived Macrophages Increase in Acute Gastrointestinal Graft-Versus-Host Disease. Transplantation and Cellular Therapy (TCT). ISSN 2666-6375. 28(5), p. 248.e1–248.e8. doi: 10.1016/j.jtct.2022.01.028.
• Remberger, Mats; Tjønnfjord, Geir Erland; Abrahamsen, Ingerid Weum; Ali, Maryan Mohamed; Myhre, Anders Eivind & Gedde-Dahl, Tobias [Show all 7 contributors for this article] (2021). Superior Graft-versus-Host Disease-Free Relapse-Free Survival in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation with Anti-Thymocyte Globulin (ATG) Compared to Matched Related Donor without ATG. Transplantation and Cellular Therapy (TCT). ISSN 2666-6375. 27(7), p. 621.e1–621.e3. doi: 10.1016/j.jtct.2021.03.019.
• Ali, Maryan Mohamed; Grønvold, Bjørn Christer Linder; Remberger, Mats; Abrahamsen, Ingerid Weum; Myhre, Anders Eivind & Tjønnfjord, Geir Erland [Show all 8 contributors for this article] (2021). Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival. Clinical Lymphoma, Myeloma & Leukemia. ISSN 2152-2650. 21(9), p. 598–605. doi: 10.1016/j.clml.2021.05.003. Full text in Research Archive
• Waidhauser, Johanna; Labopin, Myriam; Esteve, Jordi; Kröger, Nicolaus; Cornelissen, Jan & Gedde-Dahl, Tobias [Show all 17 contributors for this article] (2021). Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. Bone Marrow Transplantation. ISSN 0268-3369. 56(10), p. 2445–2453. doi: 10.1038/s41409-021-01322-w.
• Cesaro, Simone; Tridello, Gloria; Knelange, Nina Simone; Blijlevens, Nicole; Martin, Murray & Snowden, JA [Show all 29 contributors for this article] (2021). Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP–EBMT. Bone Marrow Transplantation. ISSN 0268-3369. 56(7), p. 1563–1572. doi: 10.1038/s41409-021-01212-1.
• Nagler, Arnon; Labopin, Myriam; Dholaria, Bhagirathbhai; Wu, Depei; Choi, Goda & Aljurf, Mahmoud [Show all 24 contributors for this article] (2021). Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplantation and Cellular Therapy (TCT). ISSN 2666-6375. doi: 10.1016/j.jtct.2021.11.013.
• Jørgensen, Silje Fjellgård; Buechner, Jochen; Myhre, Anders Eivind; Galteland, Eivind; Spetalen, Signe & Kulseth, Mari Ann [Show all 19 contributors for this article] (2021). A Nationwide Study of GATA2 Deficiency in Norway-the Majority of Patients Have Undergone Allo-HSCT. Journal of Clinical Immunology. ISSN 0271-9142. doi: 10.1007/s10875-021-01189-y. Full text in Research Archive Show summary

  Purpose: GATA2 deficiency is a rare primary immunodeficiency that has become increasingly recognized due to improved molecular diagnostics and clinical awareness. The only cure for GATA2 deficiency is allogeneic hematopoietic stem cell transplantation (allo-HSCT). The inconsistency of genotype-phenotype correlations makes the decision regarding "who and when" to transplant challenging. Despite considerable morbidity and mortality, the reported proportion of patients with GATA2 deficiency that has undergone allo-HSCT is low (~ 35%). The purpose of this study was to explore if detailed clinical, genetic, and bone marrow characteristics could predict end-point outcome, i.e., death and allo-HSCT. Methods: All medical genetics departments in Norway were contacted to identify GATA2 deficient individuals. Clinical information, genetic variants, treatment, and outcome were subsequently retrieved from the patients' medical records. Results: Between 2013 and 2020, we identified 10 index cases or probands, four additional symptomatic patients, and no asymptomatic patients with germline GATA2 variants. These patients had a diverse clinical phenotype dominated by cytopenia (13/14), myeloid neoplasia (10/14), warts (8/14), and hearing loss (7/14). No valid genotype-phenotype correlations were found in our data set, and the phenotypes varied also within families. We found that 11/14 patients (79%), with known GATA2 deficiency, had already undergone allo-HSCT. In addition, one patient is awaiting allo-HSCT. The indications to perform allo-HSCT were myeloid neoplasia, disseminated viral infection, severe obliterating bronchiolitis, and/or HPV-associated in situ carcinoma. Two patients died, 8 months and 7 years after allo-HSCT, respectively. Conclusion: Our main conclusion is that the majority of patients with symptomatic GATA2 deficiency will need allo-HSCT, and a close surveillance of these patients is important to find the "optimal window" for allo-HSCT. We advocate a more offensive approach to allo-HSCT than previously described.

• Kharfan-Dabaja, Mohamed A.; Labopin, Myriam; Bazarbachi, Ali; Ciceri, Fabio; Finke, J. & Bruno, Benedetto [Show all 29 contributors for this article] (2021). Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation. ISSN 0268-3369. 56(9), p. 2194–2202. doi: 10.1038/s41409-021-01317-7.
• Flygt, Hjalmar; Söderlund, Stina; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu & Mustjoki, Satu [Show all 18 contributors for this article] (2021). Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study. European Journal of Haematology. ISSN 0902-4441. p. 1–7. doi: 10.1111/ejh.13699. Show summary

  Objectives Treatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of tyrosine kinase inhibitors (TKI) and other drugs. Interferon-α in addition to TKI has shown promising efficacy but with dose-dependent toxicity and discontinuations. NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-α (PegIFN-α) in combination with dasatinib (DAS) in CML-CP. Methods Forty patients with newly diagnosed CML-CP were given DAS upfront. After month 3 (M3) 15 μg/wk of PegIFN-α was added and increased to 25 μg/wk from M7 until M15. DAS treatment was continued and adverse events and BCR-ABL1 qRT-PCR values were reported yearly after M24. Results from M1 to M18 have previously been published, and here we present long-term data. Results After 5 years of follow-up, there were no suspected unexpected serious adverse reactions, no increase in serosal effusions, no disease progressions and no CML-related deaths. Rates of MR3.0 (MMR), MR4.0 and MR4.5 were 84.6%, 64.1% and 51.3% respectively at M60, and 95% of patients reached MMR at some point during the study. Conclusion Initial addition of PegIFN-α to DAS shows good long-term efficacy without increased toxicity.

• Richter, Johan; Lübking, Anna; Söderlund, Stina; Lotfi, Kourosh; Markevärn, Berit & Själander, Anders [Show all 19 contributors for this article] (2021). Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. Leukemia. ISSN 0887-6924. 35, p. 2416–2418. doi: 10.1038/s41375-021-01173-w. Full text in Research Archive
• Andersen, Anders Mikal; Bergan, Stein; Gedde-Dahl, Tobias; Buechner, Jochen & Vethe, Nils Tore (2021). Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients. Journal of Pharmaceutical and Biomedical Analysis. ISSN 0731-7085. 203, p. 1–11. doi: 10.1016/j.jpba.2021.114216. Full text in Research Archive
• Giebel, Sebastian; Labopin, Myriam; Sobczyk-Kruszelnicka, Malgorzata; Stelljes, Matthias; Byrne, Jenny L. & Fegueux, Nathalie [Show all 100 contributors for this article] (2021). Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation. ISSN 0268-3369. 56(2), p. 481–491. doi: 10.1038/s41409-020-01050-7.
• Halaburda, Kazimierz; Labopin, Myriam; Mailhol, Audrey; Socié, Gérard; Craddock, Charles & Aljurf, Mahmoud [Show all 18 contributors for this article] (2020). Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: A study from the acute leukemia working party of the european society for blood and marrow transplantation. Haematologica. ISSN 0390-6078. 105(6), p. 1723–1730. doi: 10.3324/haematol.2019.222810.
• Divito, Sherrie J.; Aasebø, Anders Theodor Michaelsen; Matos, Tiago R.; Hsieh, Pei-Chen; Collin, Matthew & Elco, Christopher P. [Show all 25 contributors for this article] (2020). Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. Journal of Clinical Investigation. ISSN 0021-9738. 130(9), p. 4624–4636. doi: 10.1172/JCI129965.
• Tadele, Dagim Shiferaw; Robertson, Joseph; Crispin, Richard; Herrera, Carmen; Chlubnová, Markéta & Piechaczyk, Laure Isabelle [Show all 14 contributors for this article] (2020). A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. Journal of Biological Chemistry. ISSN 0021-9258. 296. doi: 10.1074/jbc.RA120.015285.
• Tvedt, Tor Henrik Anderson; Skaarud, Kristin Aneta Joan; Tjønnfjord, Geir Erland; Gedde-Dahl, Tobias; Iversen, Per Ole & Bruserud, Øystein (2020). The systemic metabolic profile early after allogeneic stem cell transplantation: Effects of adequate energy support administered through enteral feeding tube. Biology of Blood and Marrow Transplantation. ISSN 1083-8791. 26(2), p. 380–391. doi: 10.1016/j.bbmt.2019.10.005.
• Gilleece, Maria H; Labopin, Myriam; Savani, Bipin N; Yakoub-Agha, Ibrahim; Socié, Gérard & Gedde-Dahl, Tobias [Show all 16 contributors for this article] (2019). Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia. ISSN 0887-6924. 34(1), p. 87–99. doi: 10.1038/s41375-019-0527-4.
• Cremers, Eline M.P.; de Witte, Theo; De Wreede, Liesbeth C.; Eikema, Diderik-Jan; Koster, Linda & van Biezen, Anja A. [Show all 24 contributors for this article] (2019). A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma. ISSN 1042-8194. 60(10), p. 2404–2414. doi: 10.1080/10428194.2019.1594215.
• Passweg, Jakob Robert; Labopin, Myriam; Christopeit, Maximillian; Cornelissen, Jan J.; Pabst, Thomas & Soçie, Gérard J. [Show all 19 contributors for this article] (2019). Postremission consolidation by autologous hematopoietic cell transplantation (HCT) for acute myeloid leukemia in first complete remission (CR) and negative implications for subsequent allogeneic HCT in second CR: A study by the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Biology of Blood and Marrow Transplantation. ISSN 1083-8791. p. 1–6. doi: 10.1016/j.bbmt.2019.11.021. Full text in Research Archive
• Wiktor-Jedrzejczak, W.; Drozd-Sokolowska, J; Eikema, DJ; Hoek, J; Potter, M & Wulf, G [Show all 32 contributors for this article] (2019). EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-019-0448-x.
• Søraas, Arne Vasli; Matsuyama, Mieko; de Lima, Marcos; Wald, David; Buechner, Jochen & Gedde-Dahl, Tobias [Show all 12 contributors for this article] (2019). Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells. Aging Cell. ISSN 1474-9718. 18(2). doi: 10.1111/acel.12897. Full text in Research Archive
• Reikvam, Håkon; Skavland, Jørn; Gullaksen, Stein-Erik; Hovland, Randi; Gedde-Dahl, Tobias & Bruserud, Øystein [Show all 7 contributors for this article] (2018). Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case Reports in Hematology. ISSN 2090-6560. doi: 10.1155/2018/2045985. Full text in Research Archive
• Lorentino, Francesca; Labopin, Myriam; Bernardi, Massimo; Ciceri, Fabio; Socié, Gérard & Cornelissen, Jan J. [Show all 18 contributors for this article] (2018). Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. American Journal of Hematology. ISSN 0361-8609. 93(10), p. 1236–1244. doi: 10.1002/ajh.25231.
• McLornan, Donal P; Szydlo, Richard; Robin, Marie; Van Biezen, Anja A.; Koster, Linda & Blok, Henrik J P [Show all 27 contributors for this article] (2018). Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. British Journal of Haematology. ISSN 0007-1048. 182(3), p. 418–422. doi: 10.1111/bjh.15407.
• Danylesko, Ivetta; Bukauskas, Adomas; Paulson, Martin; Peceliunas, Valdas; Gedde-Dahl, Tobias & Shimoni, Avichai [Show all 10 contributors for this article] (2018). Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-018-0364-5.
• Tangen, Jon-Magnus; Tjønnfjord, Geir Erland; Gulbrandsen, Nina; Gedde-Dahl, Thobias; Stormorken, Espen & Anderson, Kristina [Show all 9 contributors for this article] (2018). Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: A retrospective, population based analysis. BMC Cancer. ISSN 1471-2407. 18:801, p. 1–9. doi: 10.1186/s12885-018-4722-x. Full text in Research Archive
• Tvedt, Tor Henrik Anderson; Hovland, Randi; Tsykunova, Galina; Ahmed, Aymen B; Gedde-Dahl, Thobias & Bruserud, Øyvind (2018). A pilot study of single nucleotide polymorphisms in the interleukin-6 receptor and their effects on pre- and post-transplant serum mediator level and outcome after allogeneic stem cell transplantation. Clinical and Experimental Immunology. ISSN 0009-9104. 193(1), p. 130–141. doi: 10.1111/cei.13124. Full text in Research Archive
• Lazarević, Vladimir L.J.; Labopin, Myriam; Depei, Wu; Yakoub-Agha, Ibrahim; Huynh, Anne & Ljungman, Per [Show all 16 contributors for this article] (2018). Relatively favorable outcome after allogeneic stem cell transplantation for BCR‐ABL1‐positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). American Journal of Hematology. ISSN 0361-8609. 93(1), p. 31–39. doi: 10.1002/ajh.24928.
• Canaani, Jonathan; Labopin, Myriam; Socié, Gérard; Nihtinen, Anne; Huynh, Anne & Cornelissen, Jan [Show all 14 contributors for this article] (2017). Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. American Journal of Hematology. ISSN 0361-8609. 92(7), p. 653–659. doi: 10.1002/ajh.24737.
• Canaani, Jonathan; Beohou, Eric; Labopin, Myriam; Socie, Gerard; Huynh, Anne & Volin, Liisa [Show all 14 contributors for this article] (2017). Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT. American Journal of Hematology. ISSN 0361-8609. 92(4), p. 344–350. doi: 10.1002/ajh.24640.
• Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof & Dumrese, Claudia [Show all 29 contributors for this article] (2017). Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. ISSN 0390-6078. 102(8), p. 1361–1367. doi: 10.3324/haematol.2017.167080. Full text in Research Archive
• Ilander, Mette; Olsson-Strömberg, Ulla; Schlums, Heinrich; Guilhot, Joëlle; Brück, Oscar & Lähteenmäki, Hanna [Show all 31 contributors for this article] (2017). Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. ISSN 0887-6924. 31(5), p. 1108–1116. doi: 10.1038/leu.2016.360.
• van Gelder, Michel; De Wreede, Liesbeth C.; Bornhäuser, Martin; Niederwieser, Dietger Walter; Karaś, Michael & Anderson, Niels Smedsgaard [Show all 31 contributors for this article] (2017). Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. ISSN 0268-3369. 52(3), p. 372–380. doi: 10.1038/bmt.2016.282.
• Robin, M; Porcher, R; Zinke-Cerwenka, W; van Biezen, A.; Volin, L. & Mufti, G [Show all 22 contributors for this article] (2017). Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: A retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplantation. ISSN 0268-3369. 52(2), p. 209–215. doi: 10.1038/bmt.2016.266.
• Poiré, Xavier; Labopin, Myriam; Maertens, Johan; Yakoub-Agha, Ibrahim; Blaise, Didier & Ifrah, Norbert [Show all 16 contributors for this article] (2017). Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Journal of Hematology & Oncology. ISSN 1756-8722. 10(1), p. 1–10. doi: 10.1186/s13045-017-0393-3.
• Fløisand, Yngvar; Lundin, Knut Erik Aslaksen; Lazarevic, Vladimir; Kristiansen, Jørn Dehli; Osnes, Liv T. N. & Tjønnfjord, Geir Erland [Show all 8 contributors for this article] (2016). Targeting integrin α4β7 in steroid-refractory intestinal graft-versus-host disease. Biology of Blood and Marrow Transplantation. ISSN 1083-8791. 23(1), p. 172–175. doi: 10.1016/j.bbmt.2016.10.009.
• Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Höglund, Martin & Dreimane, Arta [Show all 20 contributors for this article] (2016). Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. ISSN 0887-6924. 30(9), p. 1853–1860. doi: 10.1038/leu.2016.121.
• Bremer, Sara; Fløisand, Yngvar; Brinch, Lorentz; Gedde-Dahl, Thobias & Bergan, Stein (2015). Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome after Myeloablative Conditioning. Therapeutic Drug Monitoring. ISSN 0163-4356. 37(4), p. 493–500. doi: 10.1097/FTD.0000000000000180.
• Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta; Ehrencrona, Hans & Gedde-Dahl, Thobias [Show all 20 contributors for this article] (2015). Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). European Journal of Haematology. ISSN 0902-4441. 94(3), p. 243–250. doi: 10.1111/ejh.12423. Full text in Research Archive
• Hallstensen, Randi; Bergseth, Grete; Foss, Stian; Jæger, Steinar; Gedde-Dahl, Thobias & Holt, jan [Show all 14 contributors for this article] (2015). Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. ISSN 0171-2985. 220(4), p. 452–459. doi: 10.1016/j.imbio.2014.11.003. Full text in Research Archive
• Bruserud, Øystein; Tvedt, Tor Henrik Anderson; Quist-Paulsen, Petter; Ahmed, Aymen B; Gedde-Dahl, Thobias & Tjønnfjord, Geir Erland [Show all 9 contributors for this article] (2014). Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: Immunological mechanisms and the results from clinical studies. Cancer Immunology and Immunotherapy. ISSN 0340-7004. 63(8), p. 757–777. doi: 10.1007/s00262-014-1578-z.
• Mustjoki, Satu; Richter, Johan; Barbany, Gisela; Ehrencrona, Hans; Fioretos, Thoas & Gedde-Dahl, Thobias [Show all 21 contributors for this article] (2013). Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. ISSN 0887-6924. 27(7), p. 1520–1526. doi: 10.1038/leu.2013.19.
• Mellqvist, Ulf-Henrik; Gimsing, Peter; Hjertner, Øyvind; Lenhoff, Stig; Laane, Edward & Remes, Kari [Show all 25 contributors for this article] (2013). Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. ISSN 0006-4971. 121(23), p. 4647–4654. doi: 10.1182/blood-2012-11-464503.
• Gruber, Franz; Lundan, Tuija; Goll, Rasmus; Silye, Aleksandra; Mikkola, Ingvild & Rekvig, Ole Petter [Show all 11 contributors for this article] (2012). BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? Medical Oncology (MO). ISSN 1357-0560. 29(1), p. 219–226. doi: 10.1007/s12032-010-9781-z.
• Fløisand, Yngvar; Brinch, Lorentz; Gedde-Dahl, Thobias; Tjønnfjord, Geir Erland; Dybedal, Ingunn & Holte, Harald [Show all 18 contributors for this article] (2012). Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. ISSN 0268-3369. 47(12), p. 1552–1557. doi: 10.1038/bmt.2012.63.
• Simonsson, B; Gedde-Dahl, Tobias; Markevärn, B; Remes, Kari; Stentoft, Jesper & Almqvist, Anders [Show all 28 contributors for this article] (2011). Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. ISSN 0006-4971. 118(12), p. 3228–3235. doi: 10.1182/blood-2011-02-336685.
• Frøyland, Marianne; Ruffini, Pier Adelchi; Thompson, Keith M; Gedde-Dahl, Thobias; Fredriksen, Agnete & Bogen, Bjarne (2011). Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing . European Journal of Haematology. ISSN 0902-4441. 86(5), p. 385–395. doi: 10.1111/j.1600-0609.2011.01590.x.
• Johnsen, Hans; Klausen, Tobias W.; Boegsted, Martin; Lenhoff, Stig; Gimsing, Peter & Christiansen, Ilse [Show all 9 contributors for this article] (2010). Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200 Patients in Trials of the Nordic Myeloma Study Group. Clinical Lymphoma, Myeloma & Leukemia. ISSN 2152-2650. 10(4), p. 290–296. doi: 10.3816/CLML.2010.n.060.

View all works in Cristin

• Ye, Yishan; Labopin, Myriam; Chen, Jia; Wu, Depei; Gedde-Dahl, Tobias & Blaise, Didier [Show all 21 contributors for this article] (2024). Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT. Blood Cancer Journal. ISSN 2044-5385. 14(1). doi: 10.1038/s41408-024-01072-0.
• Vethe, Nils Tore; Andersen, Anders Mikal; Gedde-Dahl, Tobias; Buechner, Jochen & Bergan, Stein (2024). Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor. Therapeutic Drug Monitoring. ISSN 0163-4356. 46(3), p. 416–417. doi: 10.1097/FTD.0000000000001209.
• Flygt, Hjalmar; Söderlund, Stina; Richter, Johan; Saussele, Susanne; Koskenvesa, Perttu & Stenke, Leif [Show all 20 contributors for this article] (2024). Correction to: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial (Leukemia, (2024), 10.1038/s41375-024-02145-6). Leukemia. ISSN 0887-6924. doi: 10.1038/s41375-024-02184-z.
• Rørvik, Synne Dragesund; Abrahamsen, Ingerid Weum; Myhre, Anders Eivind; Vo, Camilla Dao; Meling, Eva Ødegaard & Bruserud, Øystein [Show all 8 contributors for this article] (2023). Kronisk transplantat-mot-vertsykdom. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(4), p. 337–341. doi: 10.4045/tidsskr.22.0525. Full text in Research Archive
• Ruggeri, Annalisa; de Wreede, Liesbeth C.; Müller, Carlheinz R.; Crivello, Pietro; Bonneville, Edouard F. & Petersdorf, Effie W. [Show all 170 contributors for this article] (2023). Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation. Haematologica. ISSN 0390-6078. 108(2), p. 645–652. doi: 10.3324/haematol.2021.280055.
• Nagler, Arnon; Ngoya, Maud; Galimard, Jacques-Emmanuel; Labopin, Myriam; Kröger, Nicolaus & Socié, Gerard [Show all 19 contributors for this article] (2022). Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT (Bone Marrow Transplantation, (2022), 10.1038/s41409-022-01825-0). Bone Marrow Transplantation. ISSN 0268-3369. doi: 10.1038/s41409-022-01853-w.
• Horn, Morten Andreas; Myhre, Anders Eivind; Prescott, Trine; Aasly, Jan; Sundal, Christina Heidemann & Gedde-Dahl, Tobias (2022). Prophylactic Allogeneic Hematopoietic Stem Cell Therapy for CSF1R-Related Leukoencephalopathy. Movement Disorders. ISSN 0885-3185. 37(5), p. 1108–1109. doi: 10.1002/mds.29011.
• Grønvold, Bjørn Christer Linder; Ali, M.M.; Remberger, M.; Mattsson, J.; Egeland, Torstein & Lundin, Katrin [Show all 13 contributors for this article] (2020). HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplantation. ISSN 0268-3369. 55(8), p. 1658–1661. doi: 10.1038/s41409-020-0827-3.
• Abrahamsen, Ingerid Weum; Grønvold, Bjørn Christer; Inderberg, Else Marit ; Mensali, Nadia; Mattsson, Jonas & Gedde-Dahl, Tobias (2020). Posttransplantation Lymphoproliferative Disease Treated by Retransplantation. Case Reports in Immunology. ISSN 2090-6609. 2020. doi: 10.1155/2020/9403123. Full text in Research Archive Show summary

  Epstein–Barr virus- (EBV-) induced posttransplantation lymphoproliferative disease (PTLD) is a life-threatening complication following allogeneic stem cell transplantation. *e main risk factor is anti-thymocyte globulin (ATG). Patients who fail first-line treatment with rituximab have a poor prognosis. *ough adoptive transfer of EBV-specific T cells is a potentially effective option, it is not readily available. In this case report, the patient developed PTLD following transplantation for aplastic anemia using ATG as part of the conditioning. He failed rituximab treatment and developed graft failure. We were aware that the stem cell donor had a recent EBV infection prior to transplantation, whereas the patient most likely was EBV negative before transplant. We describe our strategy to meet the patient’s urgent need for EBV-specific Tcells, as well as new hematopoietic stem cells. *e same donor was used for a second transplant, using peripheral blood stem cells. *e conditioning used was thiotepa/busulfan/fludarabin with a single dose of cyclophosphamide after transplant as graft-versus-host disease (GVHD) prophylaxis. *e EBV DNA levels fell when conditioning was started, and have been undetectable since day +15 and remained so till 18 months after transplantation. *e patient is doing well. *is case reports successful use of cyclophosphamide after transplantation as GVHD prophylaxis, preserving virus-specific immunity.

• Fevang, Børre; Fagerli, Unn Merete; Sorte, Hanne Sørmo; Aarset, Harald; Hov, Håkon & Langmyr, Marit [Show all 11 contributors for this article] (2018). Runaway Train; A Leaky Radiosensitive SCID with Skin Lesions and Multiple Lymphomas. Hindawi (Case Reports in Immunology). doi: 10.1155/2018/2053716.
• Bruserud, Øystein; Melve, Guro Kristin; Gedde-Dahl, Thobias & Tvedt, Tor Henrik Anderson (2018). Immunological heterogeneity of healthy peripheral blood stem cell donors?preharvesting donor characteristics, additional heterogeneity induced by granulocyte colony-stimulating factor and possible importance for outcome after allotransplantation. Expert Review of Hematology. ISSN 1747-4086. p. 1–3. doi: 10.1080/17474086.2018.1511420.
• Diep, Phoi Phoi; Melberg, Hans Olav; Brinch, Lorentz; Buechner, Jochen; Fløisand, Yngvar & Gedde-Dahl, Thobias [Show all 9 contributors for this article] (2018). Cost-utility of allogeneic hematopoietic stem cell transplantation in Norway. Bone Marrow Transplantation. ISSN 0268-3369. 53(5), p. 657–660. doi: 10.1038/s41409-018-0091-y.
• Ayuda-Duran, Maria del Pilar; Zhang, B; Piechaczyck, L.; Popa, Mihaela Lucia; Tadele, Dagim Shiferaw & Rowe, Alexander D. [Show all 12 contributors for this article] (2017). a precision medicin platform for acute myeloid leukemia to help unraveling the molecular addictions of FLT3-ITD-driven AML. Show summary

  Acute myeloid leukemia (AML) is an aggressive disease with poor prognosis (Tzelepis et al. 2016). No single driver mutation is present in all cases of AML, making its treatment a challenge (The Cancer Genome Atlas Research 2013). Current standard of care for AML is an aggressive cytostatics-based treatment that has remained unchanged for the past 30 years (Longo et al. 2015). Weak or elderly patients might not be eligible for intensive treatment, leading to poor survival rates. Many such patients are labeled as “untreatable”, although a portion of them could benefit from specific, individualized treatment. A precision medicine strategy can help to find the specific treatment for these ‘untreatable’ AML patients. Aims Drug-driven personalized medicine aims to directly test the sensitivity of primary cancer cells taken from individual AML patients to a selection of targeted cancer drugs, compare these results with drug sensitivities of healthy donor samples and select the most effective drug for each patient. This approach considers any combination of mutations or epigenetic changes that might not be found in the standard sequencing panels, an advantage when dealing with such a heterogeneous disease. Proof of principle of this strategy was recently demonstrated by FIMM (Helsinki, Finland) (Pemovska et al. 2013), not only providing immediate clinical benefit to leukemia patients, but also identifying drugs that can potentially be repurposed for future treatment of patients. Methods We have established a drug-driven personalized medicine platform for AML where we check the ex-vivo drug sensitivity and resistance of bone marrow primary cells to a panel of around 400 drugs and drug combinations covering the standard of care treatments, cancer chemotherapeutics as well as many clinically available and emerging molecularly targeted compounds. We calculate the IC50 values for all the drugs for each individual donor or patient, and then the differential drug sensitivity scores, selecting the drugs that affect preferentially the cancer cells when compared with healthy cells. To date we have successfully processed 6 healthy donors and 66 AML samples identifying subgroups of patients who respond with a similar dynamic to certain classes of drugs, as the subgroup of cells carrying internal tandem duplications in the receptor tyrosine kinase FLT3 (FLT3-ITD). Results FLT3 activating mutations, particularly FLT3-ITD, have been observed in approximately 30% of AMLs (The Cancer Genome Atlas Research 2013), and are associated with increased risk of relapse and poor clinical outcome (Abu-Duhier et al. 2008). The cellular pathways that support FLT3-ITD-driven cell proliferation and survival remain poorly understood. We discovered that FLT3-ITD-expressing AML blasts show an enhanced sensitivity to HSP90 inhibitors such as Ganetespib compared to healthy donors and any other subgroups of leukemia. In addition, HSP90 inhibitors specifically sensitize FLT3-ITD-expressing bone marrow-derived cells to TKIs, whereas cells derived from healthy donors are unaffected. HSP90 inhibitors also preferentially eradicate a population of patient-derived FLT3-ITD+ AML cells expressing leukemic stem cell markers. Conclusion In summary, our study reveals a molecular basis for HSP90 addiction of FLT3-ITD-driven AML and provides a rationale for treatment of this form of AML with HSP90 inhibitors. Session topic: 3. Acute myeloid leukemia - Biology Keyword(s): Flt3-ITD, AML

• Diep, Phoi Phoi; Melberg, Hans Olav; Brinch, Lorentz; Buechner, Jochen; Fløisand, Yngvar & Gedde-Dahl, Thobias [Show all 8 contributors for this article] (2017). Allogeneic hematopoietic stem cell transplantation in Norway 1974-2009: Cost-utility and survival in children and young adults .
• Koenecke, Christian; Heim, Dominik; Van Biezen, Anja A.; Heuser, Michael; Aljurf, Mahmoud Deeb Saeed & Kyrcz-Krzemień, Sławomira [Show all 20 contributors for this article] (2016). Outcome of patients with chronic myeloid leukemia and a low-risk score: Allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation. ISSN 0268-3369. 51(9), p. 1259–1261. doi: 10.1038/bmt.2016.97.
• Bazarbachi, Ali; Labopin, Myriam; Kharfan-Dabaja, Mohamed A.; Schwerdtfeger, Rainer; Volin, Liisa & Bourhis, Jean Henri [Show all 19 contributors for this article] (2015). Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: Outcome strongly correlates with disease status. Haematologica. ISSN 0390-6078. 101(1), p. e34–e37. doi: 10.3324/haematol.2015.135681.
• Bremer, Sara; Fløisand, Yngvar; Brinch, Lorentz; Gedde-Dahl, Thobias & Bergan, Stein (2013). Pharmacogenetics of busulfan: significant association between GSTA1 genotype, busulfan pharmacokinetics and short term toxicity. Bone Marrow Transplantation. ISSN 0268-3369. 48, p. S227–S228.
• Simonsson, Bengt; Gedde-Dahl, Thobias; Markevärn, Berit; Remes, Kari; Stentoft, Jesper & Almqvist, Anders [Show all 29 contributors for this article] (2010). MAJOR MOLECULAR RESPONSE RATE AT ONE YEAR IS HIGHER IF PEGYLATED INTERFERON ALPHA-2B IS ADDED TO IMATINIB IN NON-HR CHRONIC MYELOID LEUKEMIA PATIENTS IN IMATINIB INDUCED COMPLETE HEMATOLOGICAL REMISSION. Haematologica. ISSN 0390-6078. 95, p. 457–457.
• Giske, Liv; Stoinska-Schneider, Anna; Lund Håheim, Lise; Juvet, Lene Kristine; Gunnarsson, Ragnar & Gedde-Dahl, Thobias [Show all 8 contributors for this article] (2018). Autologous hematopoietic stem cell transplantation (AHSCT) for Diffuse Systemic Sclerosis. Health Technology Assessment. Folkehelseinstituttet. ISSN 978‐82‐8082‐944‐3. Full text in Research Archive

View all works in Cristin